A label update for the GLP-1RA semaglutide has been approved by the FDA, which allows use of semaglutide as a first-line option for adults with T2DM.
In a post-hoc analysis of the ADVANCE trial, cumulative SBP load was a better predictor of the occurrence of MACE in patients with T2DM compared with other BP measures.
Irrespective of a history of ASCVD, finerenone reduced the risk of CV events and CKD progression compared with placebo in patients with T2DM and CKD, as shown in a FIDELITY subgroup analysis.
Finerenone, a non-steroidal MRA, has been approved for the treatment of CKD in adults with T2DM. Previously, the FIDELITY study showed that finerenone improves cardiorenal outcomes in these patients. But does this also apply to HF-related outcomes?
Robert Mentz and Peter van der Meer discuss approaches to identifying and treating iron deficiency in patients with heart failure and comorbidities such as diabetes.
Prof. Kosiborod reviews the current challenges in initiating and maintaining patients on optimal RAASi therapy and approaches to improve cardiorenal outcomes in patients with heart failure and concomitant kidney dysfunction and/or diabetes.
The FIDELITY pooled analysis findings demonstrated benefits in CV and kidney outcomes with the nonsteroidal MRA finerenone. Pam Taub, Gerasimos Filippatos, and George Bakris discuss the risk factors of CKD, the importance of measuring eGFR and UACR, and how finerenone improves outcomes.
Diabetic nephropathy is one of the leading causes of ESRD. Three experts explore recent data on the use of nonsteroidal MRAs and discuss how to prevent deterioration of renal function and improve CV outcomes across the spectrum of renal decline.
AHA 2022 In the EMPA-KIDNEY trial, use of empagliflozin reduced the outcome of worsening of kidney disease or CV death compared with placebo in CKD patients. In addition, results of a meta-analysis of 13 SGLT2i trials in high-risk patients were presented.
AHA 2022 The PROMINENT trial showed that pemafibrate reduces TG, VLDL-c, remnant cholesterol and ApoCIII in patients with T2DM, mild-to-moderate hypertriglyceridemia and low HDL-c. However, it did not reduce CV outcomes.
“Heart failure is a great masquerader, it looks like lots of other conditions because some of the symptoms overlap with a lot of symptoms of other diseases” says Prof. Jhund. Together with Prof. Inzucchi he discusses the identification and treatment of patients with HFpEF.
Many patients with diabetes have unrecognized HFpEF and early identification of these patients is important. Prof. Jhund talks about the clinical challenges of HFpEF and diabetes.